BioCentury
ARTICLE | Financial News

Ablynx raises EUR 100M in bond issue

May 22, 2015 1:15 AM UTC

Ablynx N.V. (Euronext:ABLX) raised EUR 100 million ($113.9 million) in a private placement of convertible bonds with investors outside the U.S. The bonds mature on May 27, 2020, bear 3.25% interest and convert into stock at EUR 12.93, a 27% premium to Ablynx's Wednesday close of EUR 10.16.

Ablynx develops Nanobodies, therapeutic proteins based on single-domain antibody fragments. In 2H15, the company plans to begin a Phase III trial of caplacizumab (anti-vWF Nanobody), a therapy comprising Nanobodies targeting von Willebrand factor, to treat thrombotic thrombocytopenic purpura ( TTP). ...